Washington, D.C. 20549






Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 under

the Securities Exchange Act of 1934

For the month of January, 2024

Commission File Number 001-39670




(Translation of registrant’s name into English)



6 Tide Street, Suite 400

Boston, Massachusetts 02210

(Address of principal executive office)



Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐





On May 9, 2022, PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (the “Company”) announced the commencement of a $50 million share repurchase program (the “Program”) of its ordinary shares of one pence each (“Ordinary Shares”). The Company plans to execute the Program in two equal tranches, the first of which was completed on October 26, 2022. In respect of each of the two tranches, PureTech entered into an irrevocable non-discretionary instruction with Jefferies International Limited (“Jefferies”) in relation to the purchase by Jefferies of Ordinary Shares for an aggregate consideration (excluding expenses) of no greater than $25 million and the simultaneous on-sale of such Ordinary Shares by Jefferies to PureTech. Jefferies makes its trading decisions in relation to the Ordinary Shares independently of, and uninfluenced by, the Company. Purchases may continue during any close period to which the Company is subject. Any purchase of Ordinary Shares under the second tranche of the Program are carried out on the London Stock Exchange and any other UK recognized investment exchange which may be agreed, in accordance with pre-set parameters and in accordance with, and subject to limits, including those limits related to daily volume and price, prescribed by the Company’s general authority to repurchase Ordinary Shares granted by its shareholders at its most recent annual general meeting on June 13, 2023, Chapter 12 of the Financial Conduct Authority’s UK Listing Rules, Article 5(1) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) and Commission Delegated Regulation (EU) 2016/1052 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018). All Ordinary Shares repurchased under the Program will be held in treasury.

During the month ended January 31, 2024, the Company had the following daily purchases of its own Ordinary Shares under the Program through Jefferies:




Ordinary Shares


Volume Weighted

Average Price Paid

per Ordinary Share


Highest Price Paid


Lowest Price Paid

January 2, 2024    12,161    187.73p    188.00p    186.20p
January 3, 2024    89,059    192.77p    197.80p    186.80p
January 4, 2024    90,197    198.27p    199.20p    196.80p
January 5, 2024    47,027    201.07p    202.50p    200.50p
January 8, 2024    26,079    206.97p    207.50p    204.00p
January 9, 2024    92,828    209.10p    210.50p    207.00p
January 10, 2024    117,693    203.71p    207.50p    199.40p
January 11, 2024    116,937    192.39p    201.00p    188.60p
January 12, 2024    110,778    192.95p    195.60p    183.00p
January 15, 2024    69,294    188.90p    190.40p    187.00p
January 16, 2024    96,789    186.84p    188.00p    185.40p
January 17, 2024    75,968    183.04p    186.20p    181.40p
January 18, 2024    63,487    189.98p    191.40p    186.40p
January 19, 2024    75,081    188.15p    190.40p    186.40p
January 22, 2024    76,463    191.85p    194.40p    189.60p

January 23, 2024    75,402    191.64p    194.80p    189.80p
January 24, 2024    35,192    195.69p    198.00p    192.80p
January 25, 2024    46,146    196.93p    198.60p    194.40p
January 26, 2024    71,561    198.69p    201.00p    196.80p
January 29, 2024    54,835    196.22p    198.60p    194.00p
January 30, 2024    58,677    198.31p    201.50p    195.20p
January 31, 2024    85,203    197.69p    198.40p    196.20p

During the month ended January 31, 2024, the Company repurchased an aggregate of 1,586,857 Ordinary Shares. As of January 31, 2024, the Company’s issued share capital was 289,468,159 shares, 19,201,285 of which were held in treasury, resulting in total voting rights in the Company of 270,266,874 shares. To view the details of the individual transactions, please paste the following URL(s) into the address bar of your browser with respect to each individual date of repurchase under the Program:

January 2, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5020285.html

January 3, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5021785.html

January 4, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5023116.html

January 5, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5024534.html

January 8, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5026060.html

January 9, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5027519.html

January 10, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5028977.html

January 11, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5030521.html

January 12, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5031994.html

January 15, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5033545.html

January 16, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5035014.html

January 17, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5036591.html

January 18, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5038077.html

January 19, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5039559.html

January 22, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5041268.html

January 23, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5042765.html

January 24, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5044274.html

January 25, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5045798.html

January 26, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5048616.html

January 29, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5048832.html

January 30, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5050375.html

January 31, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5051986.html


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Date: February 5, 2024     By:   /s/ Daphne Zohar
      Name: Daphne Zohar
      Title: Chief Executive Officer